Temporal relationship between sarcoidosis and malignancies in a nationwide cohort of 1942 patients.

Purpose: To investigate the phenotype of sarcoidosis according to the time when a malignancy is diagnosed (preexisting to the diagnosis of sarcoidosis, concomitant, or sequential) and to identify prognostic factors associated with malignancies in a large cohort of patients with sarcoidosis.

Methods: We searched for malignancies in the SARCOGEAS cohort, a multicenter nationwide database of consecutive patients diagnosed with sarcoidosis according to the ATS/ESC/WASOG criteria. Solid malignancies were classified using the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) nomenclature, and hematological malignancies using the 2016 WHO classification.

Evaluation of the Antiproliferative Properties of CpRu Complexes Containing N-Methylated Triazaphosphaadamantane Derivatives.

Piano-stool-{CpRu} complexes containing 1,3,5-triaza-7-phosphaadamantane (PTA), -methyl-1,3,5-triaza-7-phosphaadamantane (mPTA), and 3,7-dimethyl-1,3,7-triaza-5-phosphabyciclo[3.3.1]nonane (dmoPTA) were evaluated as drugs against breast cancer.

Tetranuclear RuCu and RuNi complexes with nanomolar anticancer activity.

Complexes [{RuCp(PPh)-μ-dmoPTA-1κ:2κ-,'-CuCl}-μ-Cl-μ-OCH](CFSO)·(CHOH) (1) and [{RuCp(PPh)-μ-dmoPTA-1κ:2κ-,'-NiCl}-μ-Cl-μ-OH](CFSO) (2) have been synthesized and characterized. Their antiproliferative activities were assessed against six human solid tumours showing nanomolar GI values. The effects of 1 and 2 on SW1573 cells colony formation, HeLa cells action mechanism and their interaction with the pBR322 DNA plasmid were evaluated.

Insights into the κ-P,N Coordination of 1,3,5-Triaza-7-phosphaadamantane and Derivatives: κ-P,N-Heterometallic Complexes and a N Nuclear Magnetic Resonance Survey.

Complexes {[(PTA)CpRu-μ-CN-1:2-RuCp(PTA)-ZnCl]}·2DMSO () {[ZnCl(HO)]-(PTA-1κ:2κ)(PTA)CpRu-μ-CN-1κ:2κ-RuCp(PTA)(PTA-1κ:2κ)-[ZnCl(HO)]}Cl (), [RuCp(HdmoPTA)(PPh)(PTA)](CFSO) (), [RuCp(HdmoPTA)(HPTA)(PPh)](CFSO) (), and [RuCp(dmoPTA)(PPh)(PTA)](CFSO) () were obtained and characterized, and their crystal structure together with that of the previously published complex is reported. The behavior of the 1,3,5-triaza-7-phosphatricyclo[3.3.

The Significant Influence of a Second Metal on the Antiproliferative Properties of the Complex [Ru(η -C H )(Cl )(dmoPTA)].

Complexes [Ru(η -C H )(Cl )(HdmoPTA)](OSO CF ) (1), [Ru(η -C H )(Cl )(dmoPTA)] (2) and [Ru(η -C H )(Cl )-μ-dmoPTA-1κP:2κ N,N'-MCl ] (M=Zn (3), Co (4), Ni (5), dmoPTA=3,7-dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane) have been synthesized and characterized by elemental analysis and spectroscopic techniques.